The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Insights into direct nose to brain delivery: current status and future perspective
Open accessAbstract
Now a day's intranasal (i.n) drug delivery is emerging as a reliable method to bypass the blood-brain barrier (BBB) and deliver a wide range of therapeutic agents including both small and large molecules, growth factors, viral vectors and even stem cells to the brain and has shown therapeutic effects in both animals and humans. This route involves the olfactory or trigeminal nerve systems which initiate in the brain and terminate in the nasal cavity at the olfactory neuroepithelium or respiratory epithelium. They are the only externally exposed portions of the central nervous system (CNS) and therefore represent the most direct method of noninvasive entry into the brain. This approach has been primarily used to explore therapeutic avenues for neurological diseases. The potential for treatment possibilities with olfactory transfer of drugs will increase as more effective formulations and delivery devices are developed. Recently, the apomorphine hydrochloride dry powders have been developed for i.n. delivery (Apomorphine nasal, Lyonase technology, Britannia Pharmaceuticals, Surrey, UK). The results of clinical trial Phase III suggested that the prepared formulation had clinical effect equivalent to subcutaneously administered apomorphine. In coming years, intranasal delivery of drugs will demand more complex and automated delivery devices to ensure accurate and repeatable dosing. Thus, new efforts are needed to make this noninvasive route of delivery more efficient and popular, and it is also predicted that in future a range of intranasal products will be used in diagnosis as well as treatment of CNS diseases. This review will embark the existing evidence of nose-to-brain transport. It also provides insights into the most relevant pre-clinical studies of direct nose-brain delivery and delivery devices which will provide relative success of intranasal delivery system. We have, herein, outlined the relevant aspects of CNS drugs given intranasally to direct the brain in treating CNS disorders like Alzheimer's disease, depression, migraine, schizophrenia, etc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is non-invasive, painless, non-stressful, and relatively easy to perform without requiring a medical specialist [246,247,248].”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [247]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,978
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Letchford, K., & Burt, H. M. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.11.009 · Cited by 1,200
Bymaster, F. P. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 725
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Effect of chitosan on epithelial permeability and structure
Dodane, V. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00030-7 · Cited by 579
Tfelt‐Hansen, P. C., de Vries, P. W., & Saxena, P. R. (2000) · Drugs · doi:10.2165/00003495-200060060-00003 · Cited by 536
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Research works printed but not linked: 5
- Dhanda DS, 2005, Drug Del Tech, 5, 64
- Ghigo E, 1994, J Clin Endocrinol Metab, 78, 693
- Jenner P, 1986, Adv Neurol, 43, 629
- Mustafa G, 2012, Curr Nanosci, 29, 293
- Putheti R, 2009, J Sci Tec, 4, 1
Cited by
Sorted by citations
Nanostructured lipid carriers for site-specific drug delivery
Khosa, A., Reddi, S., & Saha, R. N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.055 · Cited by 622
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics
Bourganis, V., Kammona, O., Alexopoulos, A., & Kiparissides, C. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.05.009 · Cited by 357
Metadata
- Authors
- Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J.
- Affiliations
- Jamia Hamdard (IN)
- Corresponding author
- Ali, Javed
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2013-10-09
- Volume
- 21
- Issue
- 2
- Pages
- 75-86
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2019126236
- Cited by
- 359
- References
- 70
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 44 · 2023: 35 · 2022: 34 · 2021: 39 · 2020: 37 · 2019: 39 · 2018: 21 · 2017: 12 · 2016: 11 · 2015: 13 · 2014: 10
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug Delivery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Health Sciences › Medicine › Surgery › Head and Neck Surgical Oncology
- Keywords
- intranasal drug delivery, nose-to-brain delivery, blood-brain barrier bypass, olfactory nerve, trigeminal nerve, olfactory epithelium, dry powder formulation, brain drug delivery, neurological disorders, Alzheimer's disease, depression, migraine, schizophrenia
- MeSH terms
- Administration, Intranasal, Animals, Blood-Brain Barrier, Brain, Central Nervous System Agents, Forecasting, Humans, Nasal Mucosa, Nose, Olfactory Mucosa, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
